NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,677−0.09%VIX25.64−9.01%latest tape · as of 20:08 UTC
The Screen · Healthcare · Biotechnology
EQEquillium, Inc.
EQ · Nasdaq · USD · Market cap $86M
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price1.51 USD
Fair valueUnder review
Ethical score92.2/100
Our investment reviews on this name
2026-11-03Read Markup1.38+9.4% to today ✓Distribution gives way to Markup first Markup read since July
2026-10-23Read Distribution1.32+14.4% to today Markdown gives way to Distribution after a 43% slide in 8 weeks
2026-08-28Read Markdown2.33-35.2% to today ✓Markup gives way to Markdown after a 21% slide in 8 weeks
2026-07-02Read Markup2.94-48.6% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Equillium, Inc. holds its Distribution at $1.51. The statistical read favours the sellers, held for 95 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 95 days
Price at the screen
$1.51
Valuation
N/A trailing · -5.74 forward price to earnings
Values screen
PASS· score 92.2
Beta
1.92
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.48%
Below 33%
Interest-bearing debt is just 0.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
20.21%
Below 33%
Cash held in interest-bearing accounts and securities is 20.2% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
3.36%
Below 5%
Only 3.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Equillium, clears all five screens. Its business is in a permissible area, its debt is near-nil, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EQ's ethical verdict changes
Today EQ passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Its inputs are 11 days old; the analyst targets sit too far from the price to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EQ trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup · changed$1.38+4.5%Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 667%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it strong buy, with a mean price target of $6.
2026-10-23Distribution · changed$1.32+0.0%Entry 8
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 667%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it strong buy, with a mean price target of $6.
2026-10-16Markdown$1.32-23.3%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 23.3% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 48% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 667%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it strong buy, with a mean price target of $6.
2026-10-02Markdown$1.72-26.2%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 26.2% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 48% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 667%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it strong buy, with a mean price target of $6.
2026-08-28Markdown · changed$2.33-10.0%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 48% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 667%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it strong buy, with a mean price target of $6.
2026-07-27Markup$2.59-11.9%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 11.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 48% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 667%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it strong buy, with a mean price target of $6.
2026-07-18Markup$2.94+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 48% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 667%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it strong buy, with a mean price target of $6.
2026-07-03Markup$2.94+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (92). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$2.94Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (92). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.